BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210719
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T201427
CREATED:20210312T071709Z
LAST-MODIFIED:20210312T071709Z
UID:29322-1626652800-1626911999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Returning digitally in 2021\, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! \nFocusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation\, this is not one to miss as you seek to accelerate the development of your neurological gene therapy. \nDiscover the latest neurological targets\, familiarise yourself with the European landscape\, and debate and discuss with the leading minds of the field from the likes of UCB\, Lysogene\, UniQure and AskBio\, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s\, Parkinson’s and epilepsy. \n \nFocusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field\, this year’s 3-day agenda has been developed alongside neurological experts from AskBio\, Handl Therapeutics\, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field. \nDiscussing rare to common neurological disorders\, attend the digital meeting in July to: \n\nHear the latest clinical updates from the most advanced companies to inform your future strategies\nDiscover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities\nDiscuss how to optimise the use of preclinical models and biomarkers for improved translation and reduced risk to patients\nAsk the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disorders\nWeigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery\nRaise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programs\nBe a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses\n\nDon’t miss your opportunity to benchmark against your competitors\, hear the state of the art technology advances and research in the field\, and make new connections at the last digital European meeting\, to revolutionise the development and delivery of your neurological gene therapy.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-neurological-disorders-europe/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T201427
CREATED:20210208T085452Z
LAST-MODIFIED:20210208T085452Z
UID:28862-1626739200-1626911999@www.pharmajournalist.com
SUMMARY:In-House Impact: Life Sciences
DESCRIPTION:In-House Impact: Life Sciences is a new type of forum\, designed for and by legal leaders in the Life Sciences\, to help legal teams move from enterprise defenders to enablers of innovation and cross-functional competency. \nThis conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences. \nWe guarantee that your time out of the office and money are well spent. With thought-provoking case studies\, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers\, we’ve no doubt this strategic discussion will leave you feeling inspired to make big change. \nTo know more about In-House Impact: Life Sciences please click here.
URL:https://www.pharmajournalist.com/event/in-house-impact-life-sciences/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T201427
CREATED:20210322T111844Z
LAST-MODIFIED:20210322T111844Z
UID:29474-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Cell-Mediated Therapies for Infectious Disease Summit
DESCRIPTION:In the fight against emerging coronavirus variants\, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells. \nThe Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. See more – https://ter.li/bo7qq7 \nJoin over 80 industry and academic leaders pioneering this new paradigm of research\, and for the first time discuss novel advances in t-cell epitope-directed vaccines\, as well as CAR-T\, TCR and NK cell therapies designed to provoke durable immunity. \nWith strategic insight and clinical advances shared from Gilead\, Merck\, Vaccibody\, TScan Therapeutics and more\, join the discussion to assess: \n\nBioinformatic tools to identify immunogenic targets\nVaccine design and delivery to trigger strong T cell responses\nBridge the gap from translatable preclinical models to IND approval\n\nLeave this meeting with a greater understanding of next-generation approaches to target\, prevent and cure HIV\, EBV and SARS-CoV-2 infection. \nSee more – https://ter.li/bo7qq7
URL:https://www.pharmajournalist.com/event/cell-mediated-therapies-for-infectious-disease-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T201427
CREATED:20210414T091907Z
LAST-MODIFIED:20210414T091907Z
UID:29789-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Next Generation Food Allergy Drug Development
DESCRIPTION:In the context of dramatically increasing food allergy incidence and a breakthrough approval in the field\, the Next Generation Food Allergy Drug Development Summit will unite large pharma and innovative biotechs to overcome the unique drug development challenges involved in turning promising food allergy biologics into clinical and commercial realities. \nJoin us to investigate the latest technological innovations\, benchmark against your peers\, build global connections and streamline your drug development pipelines for food allergy\, with insights being shared from a range of companies and institutions including Prota Therapeutics\, Allergy Therapeutics\, Intrommune\, Vedanta Biosciences and University of North Carolina. \nTo know more about Next Generation Food Allergy Drug Development please click here.
URL:https://www.pharmajournalist.com/event/next-generation-food-allergy-drug-development/
LOCATION:Online | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR